Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis
1. At week 16, all rocatinlimab groups reported significant improvements in eczema severity. 2. Most treatment-related adverse events were mild-to-moderate,...
Rheumatology
Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults
1. Significantly more patients in the bimekizumab group reached ACR50 at week 16 compared to the placebo. 2. Fungal infections...
Juvenile idiopathic arthritis may be associated with an increased risk of obstructive sleep apnea
1. In this retrospective, cohort, control-matched study, a diagnosis of juvenile idiopathic diabetes was associated with an increased risk of...
Low-dose interleukin 2 may be beneficial for primary Sjögren syndrome
1. Among patients with primary Sjögren syndrome, therapy with low-dose interleukin 2 significantly improved outcomes as determined by the European...
Self-administered subcutaneous immunoglobulin as an cost-effective alternative to clinic administration
1. Self-administered subcutaneous immunoglobulin therapy in the treatment of immunodeficiencies is significantly less costly compared to clinic-administered intravenous immunoglobulin therapy....
Allopurinol does not reduce cardiovascular risk for patients with ischemic heart disease without gout
1. The composite score for non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death was comparable between allopurinol (11.0%) and usual...
Unsupervised online yoga transiently improves symptoms in patients with knee osteoarthritis
1. Compared to a control group, patients with knee osteoarthritis who engaged in online yoga had improvements in pain and...
Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases
1. An increased incidence of new cardiovascular disease was seen in individuals with autoimmune disease compared to those without. 2....
Litifilimab improves symptom burden for patients with systemic lupus erythematosus
1. Litifilimab was associated with a reduction in the number of swollen and tender joints in systemic lupus erythematosus (SLE)...
Olokizumab is noninferior to adalimumab for the treatment of rheumatoid arthritis
1. Olokizumab was superior to placebo in improving rheumatoid arthritis (RA) symptoms. 2. Olokizumab was also noninferior to adalimumab in...
